Secukinumab is a fully human IgG1 anti-IL-17A monoclonal antibody that selectively suppresses the inflammatory cascade induced by IL-17A.[19] Some phase III[19–25] clinical trials have confirmed IL-17A as an important target for the treatment of psoriasis and psoriatic arthritis. The gene discussed is IL17A; the disease is psoriatic arthritis.